Cost-Utility Analysis of Camrelizumab Versus Chemotherapy Regimens for Second-Line Treatment of Advanced or Met-astatic Esophageal Squamous Cell Carcinoma
SHI Feng-hao
JIN Min
WANG Zi-jing
Machine-generated Keywords：
Publication Date：2021-12-05
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 73-77 )